Document is current
Any future updates will be listed below
-
Authors
D’Amore, Angelica https://orcid.org/0000-0003-4960-2689
Sundberg, Maria https://orcid.org/0000-0002-6623-4411
Lin, Rui
Lubbers, Ella T. https://orcid.org/0009-0004-7776-5412
Winden, Kellen D.
Yu, Lucy
Gawlinska, Kinga
Gawlinski, Dawid https://orcid.org/0000-0002-9376-0564
Lopez, Sam G.
Choe, Yongho
Wightman, Emma V.
Liang, Yini https://orcid.org/0000-0003-2186-0117
Modi, Meera
Yuskaitis, Christopher J.
Lee, Henry Hing Cheong https://orcid.org/0000-0003-4975-7330
Rotenberg, Alexander
Sahin, Mustafa https://orcid.org/0000-0001-7044-2953
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50 HD105351)
PTEN Research foundation
- License Information
-
More Information
Article History
Received: 29 September 2023
Revised: 22 December 2024
Accepted: 30 January 2025
First Online: 14 February 2025
Competing interests
: HL and AR are co-founders of Galibra Neuroscience, Inc., and have equity in this company. Galibra Neuroscience, Inc. does not sponsor any part of this study. M. Sahin reports grant support from Biogen, Astellas, Bridgebio, and Aucta. He has served on Scientific Advisory Boards for Roche, SpringWorks Therapeutics, Jaguar Therapeutics and Alkermes.
: No human material or data were used in this study, therefore no consent forms were needed. Animal studies and all procedures here described involving animals were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) at Boston Children’s Hospital (#00002261). All experiments were conducted following approved laboratory SOPs and the approved Institutional Biosafety Committee (IBC) protocols at Boston Children’s Hospital (#07-164 & #P00001858).
